April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Therapeutic Efficacy of Topical Phosphodiesterase-4 Inhibitor in Murine Dry Eye Disease
Author Affiliations & Notes
  • A. Okanobo
    Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts
  • S. Chauhan
    Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts
  • Y. Chen
    Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts
  • Q. Zhang
    Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts
  • R. Dana
    Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  A. Okanobo, Alcon, F; S. Chauhan, None; Y. Chen, None; Q. Zhang, None; R. Dana, Alcon, F; Alcon, C.
  • Footnotes
    Support  by Alcon
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 6276. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Okanobo, S. Chauhan, Y. Chen, Q. Zhang, R. Dana; Therapeutic Efficacy of Topical Phosphodiesterase-4 Inhibitor in Murine Dry Eye Disease. Invest. Ophthalmol. Vis. Sci. 2010;51(13):6276.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of topical selective phosphodiesterase (PDE) 4 inhibitor in ameliorating dry eye disease (DED).

Methods: : Dry eye was induced in female C57BL/6 mice by exposing them to a controlled desiccating environment chamber. Formulations of PDE4 inhibitor (0.05% cilomilast), 0.1% dexamethasone and vehicle were topically applied to different groups of DED mice (n = 8 eyes/group) 3x/daily. DED was scored by corneal fluorescein staining (CFS). Immunohistochemistry and real-time PCR were performed to quantify CD11b+ infiltration and cytokines (IL-1β, IL-1α and TNF-α), mRNA expression, respectively.

Results: : DED mice which received cilomilast and dexamethasone showed a significant decrease in the CFS compared to those receiving vehicle alone [mean ± SEM (38% ± 4.8, 35% ± 5.9 vs. 19% ± 5.7, respectively; P < 0.02)], with cilomilast and dexamethasone showing a similar efficacy. Therapy with cilomilast and dexamethasone, compared to the vehicle group, significantly decreased the total number of CD11b+ cells in the cornea (133 ± 7.4 and 130 ± 6.9 vs. 161 ± 7.8, respectively; P < 0.01). The cilomilast and dexamethasone treated eyes also showed a significant decrease in the conjunctival expression of IL-1α and TNF-α (P < 0.03) compared to those receiving vehicle alone. However, only cilomilast showed a significant decrease in the conjunctival expression of IL-1β (P < 0.03). In the cornea, the treatment with cilomilast and dexamethasone showed a significant decrease expression of TNF-α (P < 0.01) compared to vehicle. However, only dexamethasone showed a significant decrease IL-1β in the cornea (P < 0.01). The decrease in the expression levels of IL-1α in the cornea, however, was not statistically significant compared to the vehicle control treated group.

Conclusions: : The reversal of clinical signs and underlying inflammatory changes by topical cilomilast treatment clearly suggests that topical PDE-4 blockade could be an effective therapeutic modality for the treatment of DED.

Keywords: cornea: tears/tear film/dry eye • inflammation • cytokines/chemokines 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×